Brief: Mustang Bio Announces Updated Interim Phase 1/2 Data For Mb-106 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia
13/12/2021 14:38
Dec 13 (Reuters) - Mustang Bio Inc MBIO.O :
* MUSTANG BIO INC -
* MUSTANG BIO ANNOUNCES UPDATED INTERIM PHASE 1/2 DATA FOR
MB-106
IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN
LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
Source text for Eikon: ID:nGNX4xdVVC
Further company coverage: MBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie